Fibrocell Science (FCSC) Trading Down 6.8%

Fibrocell Science Inc (NASDAQ:FCSC) was down 6.8% during trading on Thursday . The company traded as low as $0.66 and last traded at $0.69. Approximately 1,345,411 shares were traded during mid-day trading, a decline of 27% from the average daily volume of 1,852,137 shares. The stock had previously closed at $0.74.

A number of equities research analysts have recently commented on FCSC shares. Zacks Investment Research raised Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Friday, September 15th. HC Wainwright lifted their price objective on Fibrocell Science from $5.70 to $7.60 and gave the company a “buy” rating in a research report on Tuesday, September 26th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $7.00 price objective (up previously from $3.00) on shares of Fibrocell Science in a research report on Monday, September 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $5.21.

In other news, major shareholder Randal J. Kirk bought 2,727,273 shares of Fibrocell Science stock in a transaction that occurred on Monday, December 11th. The shares were purchased at an average price of $0.77 per share, for a total transaction of $2,100,000.21. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.10% of the stock is currently owned by company insiders.

A hedge fund recently bought a new stake in Fibrocell Science stock. Pura Vida Investments LLC bought a new stake in Fibrocell Science Inc (NASDAQ:FCSC) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 297,000 shares of the company’s stock, valued at approximately $909,000. Pura Vida Investments LLC owned about 2.02% of Fibrocell Science at the end of the most recent quarter. 55.67% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit